

EASL – AASLD JOINT MEETING

Definition, therapeutic advances and clinical endpoints in alcoholic liver disease and alcoholic hepatitis

London, United Kingdom
30 September, 1 October 2017

Organising Committee:

Philippe Mathurin, France
Vijay Shah, United States
Gyongyi Szabo, United States
Mark Thursz, United Kingdom

Saturday 30 September 2017

07:30 – 08:50 **Registration**

08:50 – 09:00 **Welcome and opening remarks**
Gyongyi Szabo and Philippe Mathurin

Session 1: Epidemiology and progression factors of ALD
Chair: Nick Sheron, United Kingdom

09:00 – 09:20 Burden and epidemiology of alcohol-related liver diseases in Europe and North America
David Leon, United Kingdom

09:20 – 09:40 Put us out of business: Role of health policy in controlling alcohol consumption
Sir Ian Gilmore, United Kingdom

09:40 – 10:00 Genetics of ALD: What do we learn from the risk loci about the disease?
Jochen Hampe, Germany

10:00 – 10:15 Discussion

10:15 – 10:35 **Coffee break and ePoster session 1**

Session 2: Translational science in ALD
Chair: Tim Morgan, United States

10:35 – 10:55 Alcohol metabolism and cellular consequences
Laura Nagy, United States

10:55 – 11:15 From microbiome to intestinal inflammation in ALD
Bernd Schnabl, United States

11:15 – 11:50 Discussion

11:50 – 13:15 Lunch and ePoster session 2+3

13:15 – 13:35	Inflammation as a driver of ALD <i>Gyongyi Szabo, United States</i>
13:35 – 13:55	Alcohol related fibrogenesis <i>Christian Trautwein, Germany</i>
13:55 – 14:15	Impaired pathways of liver regeneration in chronic liver disease: future therapeutic target for severe ALD? <i>Anna Mae Diehl, United States</i>
14:15 – 14:35	Animal models of ALD and alcoholic hepatitis: I favour the NIAAA model for targeting the key therapeutic pathways <i>Bin Gao, United States</i>
14:35 – 14:55	I favour the intragastric fat/alcohol model or targeting the key therapeutic pathways <i>Hidekazu Tsukamoto, United States</i>
14:55 – 15:10	Discussion
15:10 – 15:30	Coffee break and ePoster session 4

Session 3: Clinical challenges in the management of patients with ALD
Chair: Carolin Lackner, Austria

15:30 – 16:00	Alcohol use disorder: diagnosis and management <i>Giovanni Addolorato, Italy</i>
16:00 – 16:20	Assessing co-factors in ALD <i>Arun Sanyal, United States</i>
16:20 – 16:35	Liver histology and AH/ALD-what is its role? <i>Dina Tiniakos, United Kingdom</i>
16:35 – 16:55	Liquid biopsy and biomarkers as a diagnostic measure and surrogate end-points <i>Vijay Shah, United States</i>
16:55 – 17:15	Non-invasive assessment including imaging in early versus advanced ALD <i>Laurent Castera, France</i>
17:15 – 17:30	Discussion
17:30 – 18:00	State-of-the-Art Lecture: Molecular pathways in hepatocellular carcinoma <i>Michael Karin, United States</i>
18:00 – 19:00	Welcome reception and ePoster session 5+6
20:00	Faculty dinner

Sunday 1 October 2017

Session 4: Management and treatment of alcoholic hepatitis (AH)

Chair : John O'Grady, London, United Kingdom

- | | |
|---------------|---|
| 08:00 – 08:20 | Acute AH: Defining disease severity (severe vs. moderate AH) and prognostic models of lethality and survival
<i>Patrick Kamath, United States</i> |
| 08:20 – 08:40 | SIRS and management of infection in AH
<i>Ramon Bataller, United States</i> |
| 08:40 – 8:55 | Early liver transplantation in AH – Pro and Con debate:
I do not favour broader use of early liver transplantation for AH
<i>Michael Lucey, United States</i> |
| 8:55 - 9:10 | I favour broader use of early liver transplantation in AH
<i>Philippe Mathurin, France</i> |
| 09:10 – 09:30 | Post-transplant complications/what is specific for ALD
<i>Patrizia Burra, Italy</i> |
| 09:30 – 09:50 | Alcohol relapse after transplantation: does-it matter?
<i>Georges-Philippe Pageaux, France</i> |
| 09:50 – 10:05 | Discussion |
| 10:05 – 10:25 | Coffee break and ePoster session 7 |

Session 5: Clinical trial design and end-points: perspectives of agencies

Chair : Helmut Seitz, Germany

- | | |
|---------------|--|
| 10:25 – 10:45 | Cost and mortality attributed to ALD
<i>Rehm Jürgen, Canada</i> |
| 10:45 – 11:05 | Regulatory process to validate biomarkers and end-points for drug approval: specific requirements for AH
<i>Christopher Leptak, United States</i> |
| 11:05 – 11:25 | EMA process to validate end-points for drug approval: specific requirements for AH
<i>EMA</i> |
| 11:25 – 11:40 | Discussions |
| 11:40 – 13:00 | Lunch and ePoster Session 8 |

Session 6: Future development of drugs in alcoholic hepatitis: Perspectives of the investigators

Chair: Laurent Spahr, Switzerland

13:00 – 13:20	Patient characteristics and end-points in clinical trials for early ALD <i>Helena Cortez Pinto, Portugal</i>
13:20 – 13:40	Current treatments in alcoholic hepatitis (lessons learned) and ongoing clinical trials <i>Mark Thursz, United Kingdom</i>
13:40 – 14:00	Clinical trial design: What is the optimal plan of development from phase I to Phase III? <i>Alexandre Louvet, France</i>
14:00 – 14:20	How can large epidemiologic studies, registries and bio-banks may help in the setting of AH and ALD <i>Alexander Krag, Denmark.</i>
14:20 – 14:40	Lessons learned from NASH CRN and DILI network on clinical networks, sample and data collection <i>Naga Chalasani, United States</i>
14:40 – 15:00	Which therapeutic targets will be the most attractive in the future? <i>Craig McClain, United States</i>
15:00 – 15:30	Break and poster session

Session 7: Future development of drugs in alcoholic hepatitis: Industry perspectives

Chair: Mack Mitchell, USA

15:30-16:45	3-4 pharma leaders to give a brief, 5-8 min overview of their plans/perspectives/challenges on clinical trials in ALD/AH Give each 15 min (presentation+ discussion)
16:45	Discussions & Closing Remarks <i>Vijay Shah and Mark Thursz</i>